Reteplase
 | This articlerelies largely or entirely on asingle source.(September 2020) |
| Clinical data | |
|---|---|
| Trade names | Retavase, Retefuse, Rapilysin, Mirel, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1736H2671N499O522S22 |
| Molar mass | 39589.75g·mol−1 |
| (verify) | |
Reteplase,trade names includeRetavase,is athrombolytic drug,used to treatheart attacksby breaking up theclotsthat cause them.
Reteplase is a recombinant non-glycosylated form of humantissue plasminogen activator,which has been modified to contain 357 of the 527amino acidsof the originalprotein.It is produced in thebacteriumEscherichia coli.[citation needed] Reteplase was approved for use in 1996.[1]
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longerhalf-lifeof 13–16 minutes. Reteplase also bindsfibrinwith lower affinity than alteplase, improving its ability to penetrate into clots.
As reteplase is able to penetrate inside the thrombi, an enhanced fibrinolytic activity will be achieved → rapid reperfusion → low incidence of bleeding.
References
[edit]- ^Mohammadi E, Seyedhosseini-Ghaheh H, Mahnam K, Jahanian-Najafabadi A, Mir Mohammad Sadeghi H (2019)."Reteplase: Structure, Function, and Production".Advanced Biomedical Research.8:19.doi:10.4103/abr.abr_169_18.PMC6446582.PMID31016177.
 | Thisdrugarticle relating to thebloodandblood forming organsis astub.You can help Wikipedia byexpanding it. |